Immunovant and Moderna stocks rose after positive trial results and a patent dispute resolution with a $950 million payout.
Immunovant (IMVT) shares reached an 18-month high after its experimental rheumatoid arthritis drug, IMVT-1402, showed a 72.7% response rate in patients with difficult-to-treat symptoms over 16 weeks. The results were described as “highly compelling” by an analyst, driving investor optimism.
Moderna (MRNA) stock climbed following a $950 million settlement in a yearslong patent dispute with Arbutus Biopharma and Roivant. The resolution removes a key legal overhang for the company, which has faced multiple intellectual property challenges in recent years.
The moves reflect renewed confidence in both companies’ pipelines and legal positioning, with investors focusing on near-term catalysts in biotech.